Raja Atreya

Friedrich-Alexander-Universität Erlangen-Nürnberg — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

66h-index16.7kcitations647works7.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(376), Microscopic Colitis(212), Helicobacter pylori-related gastroenterology studies(77), Eosinophilic Esophagitis(63), Immunodeficiency and Autoimmune Disorders(45)

Publications641 total

Tools and Advanced Imaging Technologies for Assessing Intestinal Epithelial Barrier Integrity: A Systematic Review

American Journal of Physiology-Gastrointestinal and Liver Physiology·2026

Tools and Advanced Imaging Technologies for Assessing Intestinal Epithelial Barrier Integrity: A Systematic Review.

Open Access CRIS of the University of Bern·2026Open Access

Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study

The Lancet. Gastroenterology & hepatology·2026

Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease

The American Journal of Gastroenterology·2026Open Access

DOP057 Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials

Journal of Crohn s and Colitis·2026

P1159 Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials

Journal of Crohn s and Colitis·2026Open Access

P1032 Response to Advanced Therapies in Chronic Pouchitis Is Independent of Exposure to Similar Advanced Therapy in Ulcerative Colitis before Colectomy

Journal of Crohn s and Colitis·2026

P1095 Effectiveness of First- and Second-Line Advanced Therapy in Microscopic Colitis: A Real-World Cohort Study

Journal of Crohn s and Colitis·2026Open Access

P0805 Predictors of Endoscopic Remission at 1 Year in Patients with Ulcerative Colitis Treated with Guselkumab: Post-hoc Analyses of the QUASAR Trial

Journal of Crohn s and Colitis·2026Open Access

P0868 Obefazimod enhances miR-124 expression in blood and colon tissue and reduces the key inflammatory cytokines IL-17A and IL-6 in serum of patients with moderate-to-severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials

Journal of Crohn s and Colitis·2026Open Access

P0950 CD19-CAR-T-cell therapy in multidrug-resistant ulcerative colitis: Clinical results and effects on microbiome composition and B-cell subsets

Journal of Crohn s and Colitis·2026Open Access

P0742 A Postmarketing, Prospective, Noninterventional Study Evaluating the Real-World Clinical Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease: Interim Results From the APPRISE Study

Journal of Crohn s and Colitis·2026

P0923 Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Journal of Crohn s and Colitis·2026

P1102 Impact of Disease Duration on Clinical and Endoscopic Responses at 1 Year in Patients with Crohn’s Disease Treated with Guselkumab: Pooled Analysis of the GALAXI 2 & 3 Studies

Journal of Crohn s and Colitis·2026Open Access

DOP061 Improvements in patient-reported, disease-specific and overall quality-of-life among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Journal of Crohn s and Colitis·2026Open Access

P0492 Deep learning for automated and objective in vivo assessment of intestinal epithelial barrier in IBD using probe-based confocal laser endomicroscopy

Journal of Crohn s and Colitis·2026

P0895 Long-Term Efficacy of Upadacitinib in Patients With Moderate-to-Severe Crohn’s Disease and Prior Biologic Use

Journal of Crohn s and Colitis·2026

DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study

Journal of Crohn s and Colitis·2026

DOP031 Analysis of Long-Term Safety and Efficacy of Risankizumab in Patients With Moderate-to-Severe Crohn’s Disease: 3-Year Results From the SEQUENCE Study

Journal of Crohn s and Colitis·2026

DOP004 Durable Efficacy of Risankizumab Through Week 148 in Patients With Moderate-to-Severe Crohn’s Disease: A Post Hoc Analysis of Part 2 of the SEQUENCE Study

Journal of Crohn s and Colitis·2026

page 1 of 33Next →

Frequent Co-authors

Markus F. Neurath(38), Christoph Becker(10), Stefan Wirtz(9), Timo Räth(9), Jonas Mudter(8), Imke Atreya(8), Clemens Neufert(7), Maximilian J. Waldner(7), Peter R. Galle(6), Michael Vieth(6), Sebastian Zundler(6), Britta Siegmund(6), Brigitte Bartsch(5), Hans A. Lehr(5), Stefan Rose‐John(5), Kai Hildner(5), Geert D’Haens(5), Benno Weigmann(4), Peter Bossuyt(4), Jürgen Siebler(4)